Indeed, we observed patterns of antigen coexpression on AML blasts (Fig. 2c,d) including statistically significant coexpression of U5 snRNP200 with CD47 (P = 0.002) and TIM-3 (P < 0.0001), two antigens under evaluation using separate therapeutic antibodies in phase 2–3 clinical trials for patients with AML or myelodysplastic syndrome currently21. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.